NDC 63629-2397-01 - Mesalamine
This NDC is not currently matched to an FDA NDC product listing in FDA.report, but it is a valid NDC-form code. FDA.report is showing the available DailyMed label context for the product root.
- Product NDC
- 63629-2397
- Requested NDC
- 63629-2397-01
- Package NDCs from labels
- 63629-2397-1, 63629-2397-01
- Manufacturer
- Bryant Ranch Prepack
- Effective date
- 2024-06-28
- Current FDA listing
- Not matched in FDA.report NDC product tables
DailyMed Labels#
| Label | Manufacturer | Effective date | Type |
|---|---|---|---|
| Mesalamine - Bryant Ranch Prepack | Bryant Ranch Prepack | 2024-06-28 | HUMAN PRESCRIPTION DRUG LABEL |
DailyMed Package Descriptions#
| Package NDC | Product | Description | Form | Quantity | Strength | SPL version |
|---|---|---|---|---|---|---|
| 63629-2397-1 | Mesalamine | 5 in 1 CARTON | SUPPOSITORY | 5 | 103 | |
| 63629-2397-1 | Mesalamine | 6 in 1 PACKAGE | SUPPOSITORY | 6 | 103 |
DailyMed Dashboard NDC Coverage#
| NDC | Dashboard title | SPL version | Validation | Dashboard ZIP |
|---|---|---|---|---|
| 63629-2397 | MESALAMINE SUPPOSITORY [BRYANT RANCH PREPACK] | 103 | Current NDC, Legacy NDC, 2 package rows | 20240629_06792d20-d7e9-4b66-a4cb-cd0cf1a2db25.zip |
DailyMed Billing Units#
| Package NDC | Billing unit | Product NDC | DailyMed indexing SPL | SPL version | Effective |
|---|---|---|---|---|---|
| 63629-2397-1 | EA - Each | 63629-2397 | fe8dea23-de24-4c10-8fd7-d6c94c6ef06a | 1 | 2021-06-02 |
openFDA label cross-check#
OpenFDA label data provides additional search and identifier links. DailyMed’s Structured Product Label is the canonical label on FDA.report. Matching records are deduplicated before they are shown below.
| Brand | Generic | Manufacturer | SPL set ID | Effective date | Available safety fields | Join |
|---|---|---|---|---|---|---|
| Mesalamine | MESALAMINE | Ingenus Pharmaceuticals, LLC | 58503afe-b8d4-4710-a194-e3acd64ecf1f | 2026-11-05 | Warnings, Adverse reactions | 4Q81I59GXC |
| MESALAMINE | MESALAMINE | KLM Laboratories Private Limited | 54cfed92-5e28-4a4d-a70f-2a60b5b54c12 | 2026-11-03 | Warnings, Adverse reactions | 4Q81I59GXC |
| Mesalamine | MESALAMINE | Aurobindo Pharma Limited | d6c0fc76-644e-4301-9672-f432061e3d37 | 2026-11-02 | Warnings, Adverse reactions | 4Q81I59GXC |
| mesalamine | MESALAMINE | Zydus Pharmaceuticals USA Inc. | 533bfaf5-0add-4b49-a4f2-ddea2b83f65d | 2026-10-27 | Warnings, Adverse reactions | 4Q81I59GXC |
| Lialda | MESALAMINE | Takeda Pharmaceuticals America, Inc. | 3098a080-be86-4265-9818-7fc4beab77b7 | 2026-10-26 | Warnings, Adverse reactions | 4Q81I59GXC |
| Mesalamine | MESALAMINE | Takeda Pharmaceuticals America, Inc. | 4e3b6325-a5bf-4c47-931c-142c0e4d7c3a | 2026-10-23 | Warnings, Adverse reactions | 4Q81I59GXC |
| Pentasa | MESALAMINE | Takeda Pharmaceuticals America, Inc. | e39d9a3d-5d3a-4bb6-aab1-fdbb2a598606 | 2026-10-23 | Warnings, Adverse reactions | 4Q81I59GXC |
| APRISO | MESALAMINE | Salix Pharmaceuticals, Inc. | 7951139c-b271-45a4-b523-34b23800917b | 2026-10-22 | Warnings, Adverse reactions | 4Q81I59GXC |
| Mesalamine | MESALAMINE | Zydus Pharmaceuticals USA Inc. | cd8493f7-91fd-4c2d-b3d7-c1301825586b | 2026-10-22 | Warnings, Adverse reactions | 4Q81I59GXC |
| Mesalamine | MESALAMINE | Ascend Laboratories, LLC | 43f69db3-81ac-4da4-a61f-fbba6299d9c2 | 2026-10-19 | Warnings, Adverse reactions | 4Q81I59GXC |
| Canasa | MESALAMINE | Allergan, Inc. | 89d91601-152b-4398-bebe-af1c023e9935 | 2026-10-14 | Warnings, Adverse reactions | 248420 4Q81I59GXC |
| Mesalamine | MESALAMINE | Teva Pharmaceuticals, Inc. | e3b84397-a5a5-40cf-8145-0584103d465f | 2026-09-22 | Warnings, Adverse reactions | 4Q81I59GXC |
| Mesalamine | MESALAMINE | Teva Pharmaceuticals USA, Inc. | 6fd0a906-e1b5-4238-a79b-a195510ddc84 | 2026-09-21 | Warnings, Adverse reactions | 4Q81I59GXC |
| Mesalamine | MESALAMINE | American Health Packaging | c1ed6fcc-7fd4-4b8a-9ddb-e772ea930e9e | 2026-09-17 | Warnings, Adverse reactions | 4Q81I59GXC |
| mesalamine | MESALAMINE | Zydus Pharmaceuticals USA Inc. | ad8c7930-92e2-4372-a874-da22b9ae333e | 2026-09-17 | Warnings, Adverse reactions | 4Q81I59GXC |
| Mesalamine | MESALAMINE | Amneal Pharmaceuticals LLC | 00f77203-3615-47e8-ae25-6e1cf8a2a00a | 2026-09-16 | Warnings, Adverse reactions | 4Q81I59GXC |
| Rowasa | MESALAMINE | Viatris Specialty LLC | e505ab99-1943-4216-a178-4d5dbe64e3b2 | 2026-08-03 | Warnings, Adverse reactions | 4Q81I59GXC |
| mesalamine | MESALAMINE | Major Pharmaceuticals | 14ac4435-903b-41f5-a3c4-8c73de3e4cef | 2026-07-27 | Warnings, Adverse reactions | 4Q81I59GXC |
| Mesalamine | MESALAMINE | Sandoz Inc | 47b5d1ee-b439-4ccb-9b01-c0875ccd748a | 2026-06-30 | Warnings, Adverse reactions | 4Q81I59GXC |
| Mesalamine | MESALAMINE | Nuvaila Limited | 875d573f-99a1-426a-8321-4d511690d503 | 2026-06-03 | Warnings, Adverse reactions | 4Q81I59GXC |
Reported adverse events (FAERS/openFDA)#
Adverse event summaries are temporarily unavailable. Other product information remains available.